Podcast Episodes
Back to Search
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer
Season 3 Episode 336
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
2 years, 3 months ago
Episode 335: Novel immune therapies for renal cancer
Season 3 Episode 335
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at tim…
2 years, 3 months ago
Episodio 334 en español: Tres Uramigas ASCO 2024
Season 3 Episode 334
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
2 years, 3 months ago
Episode 333: The Uromigos Cup - The Netherlands
Season 3 Episode 333
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
2 years, 3 months ago
Episode 332: The Uromigos Cup - Germany's Entry
Season 3 Episode 332
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
2 years, 4 months ago
Episode 331: AUA 2024 NMIBC Highlights
Season 3 Episode 331
Aditya Bagrodia describes three new drugs/studies in NMIBC.
2 years, 4 months ago
Episode 330: ASCO 2024 Highlights
Season 3 Episode 330
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
2 years, 4 months ago
Episode 329: Japan in the Uromigos Cup qualifying round
Season 3 Episode 329
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
2 years, 4 months ago
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies
Season 3 Episode 328
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
2 years, 4 months ago
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates
Season 3
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
2 years, 4 months ago